Ç. Ünal Et Al. , "Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey," Frontiers in Oncology , vol.13, 2023
Ünal, Ç. Et Al. 2023. Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey. Frontiers in Oncology , vol.13 .
Ünal, Ç., Özmen, T., Ordu, Ç., Pilanci, K. N., İlgün, A. S., Gökmen, E., ... Almuradova, E.(2023). Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey. Frontiers in Oncology , vol.13.
Ünal, Çağlar Et Al. "Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey," Frontiers in Oncology , vol.13, 2023
Ünal, Çağlar Et Al. "Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey." Frontiers in Oncology , vol.13, 2023
Ünal, Ç. Et Al. (2023) . "Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey." Frontiers in Oncology , vol.13.
@article{article, author={Çağlar Ünal Et Al. }, title={Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey}, journal={Frontiers in Oncology}, year=2023}